Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride

被引：0
作者：
Massimiliano Pacilio
Guido Ventroni
Giuseppe De Vincentis
Bartolomeo Cassano
Rosanna Pellegrini
Elisabetta Di Castro
Viviana Frantellizzi
Giulia Anna Follacchio
Tatiana Garkavaya
Leda Lorenzon
Pasquale Ialongo
Roberto Pani
Lucio Mango
机构：
[1] Azienda Ospedaliera San Camillo Forlanini,Department of Medical Physics
[2] Azienda Ospedaliera San Camillo Forlanini,Department of Nuclear Medicine
[3] “Sapienza” University of Rome,Department of Radiological, Oncological and Anatomo Pathological Sciences
[4] “Sapienza” University of Rome,Postgraduate School of Medical Physics
[5] “Sapienza” University of Rome,Department of Molecular Medicine
[6] Azienda Ospedaliera San Camillo Forlanini,Department of Radiology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2016年 / 43卷
关键词：
Bone metastases; Ra-dichloride; Radionuclide therapy; Dosimetry;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：21 / 33
页数：12
相关论文
共 156 条
[1]  
Coleman RE(2006)Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 6243s-6249s
[2]  
Sgouros G(2010)MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy J Nucl Med 51 311-328
[3]  
Roeske JC(2012)A bone marrow toxicity model for Ra-223 α-emitter radiopharmaceutical therapy Phys Med Biol 57 3207-3222
[4]  
McDevitt MR(2005)First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases Clin Cancer Res 11 4451-4459
[5]  
Palm S(2007)Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 587-594
[6]  
Allen BJ(2013)A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer Eur Urol 63 189-197
[7]  
Fisher DR(2014)Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-Dichloride J Nucl Med 55 268-274
[8]  
Hobbs RF(2012)A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer Eur J Cancer 48 678-686
[9]  
Song H(2006)Radiotoxicity of the α-emitting bone-seeker Ra-223 injected intravenously into mice: histology, clinical chemistry and hematology In Vivo 20 325-331
[10]  
Watchman CJ(2013)Targeted α-particle therapy of bone metastases in prostate cancer Clin Nucl Med 38 966-971
12345678910